- Home
- ABTC vs ASMB Comparison
ABTC vs ASMB Comparison
Compare ABTC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTC | ASMB |
|---|---|---|
| Founded | 2024 | 2005 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.3M | 512.1M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ABTC | ASMB |
|---|---|---|
| Price | $45.35 | $248.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.00 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 1.5M | 244.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.67 | ★ 91.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,164,000.00 | N/A |
| Revenue This Year | $79.69 | N/A |
| Revenue Next Year | $50.64 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 801.52 | N/A |
| 52 Week Low | $0.56 | $20.23 |
| 52 Week High | $10.24 | $39.71 |
Technical Indicators
Market Signals| Indicator | ABTC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 65.52 | 73.33 |
| Support Level | $4.98 | $25.86 |
| Resistance Level | $9.33 | $39.17 |
| Average True Range (ATR) | 0.62 | 1.79 |
| MACD | 0.05 | 0.79 |
| Stochastic Oscillator | 77.53 | 97.91 |
Price Performance
Historical ComparisonAbout ABTC American Bitcoin Corp.
American Bitcoin Corp is a Bitcoin accumulation platform that integrates scaled Bitcoin mining operations with disciplined accumulation strategies. Its business is engaged in the operation of application-specific integrated circuit ("ASIC") miners for mining Bitcoin and the strategic accumulation of a Bitcoin reserve.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.